To determine whether CXCR7 expression further increases as enzalutamide resistant PCa progresses to NEPC with a gain of neuroendocrine features and/or loss of AR expression (7), we examined several gene expression data sets of human PCa samples. This evidence concerns the gene AR and posterior cortical atrophy.